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Histology, treatment and duration in relation to the incidence and survival. JAMA 1966; 197:118-24 Medicines', and discussed the roles of the pharmaceutical industry in design and presentation, and the doctor in the prescribing of medicines. It then went on to examine, in some-detail the pharmaceutical aspects of containers and storage of medicines, particularly in the home, and the importance ofpublic education in their safe handling. Its second meeting, on 12 October 1988, was devoted to the critical scrutiny of 'Restrictive drug listsa worldwide controversy'. The United Kingdom came into this fairly late in the day, and the longer experiences ofAustralia, Sweden, and other countries were reviewed by Dr D de Souza (Australia) and Dr I Angenas (Sweden). The philosophy underlying the British system introduced in April 1985, anda review of its practice was presented by Dr E L Harris (London), who indicated that its primary objective of saving £75 million per year in drug costs had been achieved, and that it had increased the awareness of doctors about their prescribing habits.
Dr L Gerlis (London) conceded that the limited extent ofthe present restricted list had not seriously compromised the income, and so the research expenditure, of most pharmaceutical companies in Britain, but was nevertheless concerned that this scheme was only the thin end of a very thick wedge which could have a serious impact on drug innovation.
A recurring criticism of the scheme from the floor was the lack of information about the influence ofthe restrictive list on drug prescribing and sales. Such information was provided by Mr J S Burton (London), who showed that the scheme had resulted in a reduction of at least 20% in the value of sedative and tranquilizer prescriptions written by general practitioners. Prescriptions for cough medicines, vitamins, antacids and analgesics had also been ignificantly reduced, but there had been a substantial increase in their OTC sales. There was also evidence that a switch to more expensive alternatives (e.g. H2 receptor antagonists) had taken place. These findings were extended and reinforced by presentations on the influence of the restrictive list scheme on the community pharmacist (Mr D Coleman, Norfolk) and the prescribing general practitioner (Dr J Gilleghan, Edinburgh). Undoubtedly there were, and still are, problems between pharmacists and doctors in implementing the system, and the participants seemed to be in general agreement that more consultation between government and the professions should have taken place to avoid these and other logistic problems such as pharmacy drug stocks and the limited availability of a small number of 'white-listed' preparations. In general, however, they concluded that the introduction of the list had probably done little harm and may, indeed, have done some good by accelerating the development of local formularies, both in hospitals and general practice. Although thousands of drugs and formulations are listed in the Brtih -National F.ormu ay, most doctors already restrict their prescribing acrding to their experience and local advice from practice colleagues and hospital consultants. The distillation of such local prescribing 0141-0768/89/ 020117-02/$02.00/0 01989 The Royal Society of Medicine practice into formularies covering all groups of drugs would probably render unnecessary any further extension of a central government imposed restrictive list.
This optimistic conclusion naturally pointed the way to the next meeting of the Forum on 17 March 1989 which will be on 'Drug formulariesthe way forward, and will, amongst other things, provide guidance on the establishment of formularies in hospital and in general practice. Professor Anthony Dayan introduced the meeting, which was aimed at increasing understanding of the ways in which scientific ideas could be developed and exploited by industry. He pointed out that for many years there had been a tradition oflinks between the academic community and the pharmaceutical industry, but there were now opportunities for similar cooperation in other areas. He hoped that this meeting would facilitate this process by permitting an exchange of information on what was needed, where the opportunities were, and how they could best be exploited.
Mr L Jenkins (Wellcome Research Laboratories, Beckenham) explained how an idea could be developed for commercial exploitation by the pharmaceutical industry. He stressed that the development of any idea would take time, and that the chances of financial success with any one product were usually small. As an example he pointed out that a newly synthesized compound had about a 1:10 000 chance of reaching the market place. Any idea was likely to take between 5 and 20 years to pass through the necessary development stages, including the required toxicity testing.
Funding for the development of a product could come from a variety of sources including Government, the City, contract houses or small businesses using venture capital. Laboratory and human resources and appropriate scientific and business expertise was necessary to ensure that the many pitfalls were avoided. At the end of all this, and usually following expenditure of several million pounds, a dossier of data on a new pharmaceutical product on the safety, efflcacy and quality ofthe product had to be submitted to the licensing authority. Once licensed the product still needed to be marketed successfully. Even then, once in clinical use it could turn out to be less effective than anticipated, and so fail to capture its predicted market-share and therefore fail to produce the expected return on the investment. Mr Jenkins said there were several pitfalls that university departments had to be aware of if they wished to develop a discovery commercially. The academic's natural impulse to tell everyone about an exciting new discovery had to be curbed if the idea was to be developed as a commercial proposition. Once a discovery had been published, then intellectual property rights could not be established for the discovery. If there were none then it would not be worth investing in. Even a presentation in a closed meeting, or on a poster, would seriously undermine any chance of establishing intellectual property rights to a discovery, so a department that was serious about developing potentially commercial ideas needed to develop established procedures for its personnel to follow.
Intellectual property rights might be established by obtaining copyright on material, or by establishing the discovery as industrial property. This could be done by patenting the discovery, or by a variety of other routes. Patenting was not always the best option, for example monoclonal antibodies were not adequately protected by a patent, and better protected by making them a trade secret.
To patent a discovery, Mr Jenkins explained, one needed a full description of the invention which was then filed in the Patent Office. The idea, concept, material, substance or process must be new, not obvious and industrially applicable. Patents were only effective nationally and therefore had to be filed separately in all countries ofinterest. They prevented exploitation by others for a limited period only. In effect, the Patent Office restricts exploitation by others in return for public disclosure ofthe discovery. A 'trade secret' does not have this element of 'quid pro quo'.
The other important factor in developing a discovery is finding a suitable industrial partner. Such a partner should ideally have integrity, technical competence, vision, commercial capability, financial backing and an appropriate legal relationship with the discoverer! This last point is particularly important, since one cannot assume that the developer and the discoverer will continue to agree on all matters during the development process. Agreement therefore on secrecy, research collaboration, development and licensing needs to be reached at an early stage.
The division of labour between the partners can vary. The researcher can adopt a purely entrepreneurial approach (which is very difficult to succeed in) or the entire development can be handed over to the industrial partner. Any intermediate stage is also possible. What is important is to have an innovative and flexible approach to exploitation to enable the inevitable unexpected difficulties to be dealt with successfully. On the academic side, a positive structure to the research environment, with frequent reviews ofresearch to identify exploitable ideas at an early stage and to ensure that they are kept secret is also important.
Dr J Cavalla (Wyeth Laboratories, at Maidenhead) then spoke about 'What Industry Wants from 0141-0768/89/ 020118-044/02.00/0 ©1989 The Royal Society of Medicine
